Vaxxel

Executive Summary

Vaxxel is a French biotechnology company pioneering next-generation intranasal vaccines using its proprietary METAVAC® live attenuated viral vector platform. Founded in 2016 and based in Lyon, the company is initially targeting respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), two major respiratory pathogens with significant unmet medical need. The METAVAC® platform is designed to be multivalent and delivered via the nasal route, potentially offering easier administration and improved mucosal immunity compared to traditional injectable vaccines. Vaxxel is currently in the preclinical stage, focusing on advancing its lead candidates toward clinical development. While the company has not disclosed funding rounds or valuation, its innovative approach and focus on high-burden respiratory diseases position it as an interesting player in the vaccine landscape. Success will depend on demonstrating safety and efficacy in clinical trials, as well as securing partnerships and funding to support development.

Upcoming Catalysts (preview)

• Q1 2027Initiation of Phase 1 clinical trial for RSV vaccine candidate30% success
• H2 2026Publication of preclinical proof-of-concept data for HMPV vaccine60% success
• Q4 2026Series A financing round to support clinical development50% success